Raphael Röthlisberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raphael Röthlisberger has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Collene E. Anderson
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland
2 shared publications - George Niklaus Thalmann
Department of Urology, University of Bern, 3010 Bern, Switzerland
2 shared publications - Laila Schneidewind
Department of Urology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland
2 shared publications - Lorenz Leitner
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland
2 shared publications - Martina Daniela Liechti
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland
2 shared publications - Nicola Giudici
Department of Urology University Hospital of Bern Bern Switzerland
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in Scientific Reports
Patient-reported burden and adverse events of urodynamic investigation in adults with neurogenic lower urinary tract dysfunction
Urodynamic investigation (UDI) is the gold standard for evaluating refractory lower urinary tract symptoms but may cause pain, emotional discomfort, and adverse events, particularly urinary tract infections. In this secondary analysis of a randomized controlled trial, adults undergoing UDI for neurogenic lower urinary tract dysfunction rated pain and emotional discomfort on an 11-point numeric rating scale (0–10), with ≥ 4 defining moderate-to-severe burden; a structured telephone interview at 7–14 days assessed post-procedural adverse events. Among 490 patients, most reported low pain and emotional discomfort (median 2, IQR 0–4 and 0–5). Pain did not differ by sex, whereas emotional discomfort was higher in females (median 2.5 vs 1; p = 0.004). Post-procedural symptoms included pain (30%), worsening lower urinary tract symptoms (18%), and macrohematuria (8%); 99% were transient. Urinary tract infection occurred in 6% and was associated with pre-procedural bacteriuria (OR 6.69; 95% CI 2.15–20.81). Assuming risk equalization, the number needed to treat to prevent one infection was 15 (95% CI 9.6–38.6). In conclusion, UDI is generally well tolerated, although approximately one-third of patients experience moderate-to-severe pain or emotional discomfort. Pre-procedural bacteriuria increases infection risk, but the number needed to treat does not support antibiotic prophylaxis.
- 12 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessPatient-reported burden and adverse events of urodynamic investigation in adults with neurogenic lower urinary tract dysfunction
Urodynamic investigation (UDI) is the gold standard for evaluating refractory lower urinary tract symptoms but may cause pain, emotional discomfort, and adverse events, particularly urinary tract infections. In this secondary analysis of a randomized controlled trial, adults undergoing UDI for neurogenic lower urinary tract dysfunction rated pain and emotional discomfort on an 11-point numeric rating scale (0–10), with ≥ 4 defining moderate-to-severe burden; a structured telephone interview at 7–14 days assessed post-procedural adverse events. Among 490 patients, most reported low pain and emotional discomfort (median 2, IQR 0–4 and 0–5). Pain did not differ by sex, whereas emotional discomfort was higher in females (median 2.5 vs 1; p = 0.004). Post-procedural symptoms included pain (30%), worsening lower urinary tract symptoms (18%), and macrohematuria (8%); 99% were transient. Urinary tract infection occurred in 6% and was associated with pre-procedural bacteriuria (OR 6.69; 95% CI 2.15–20.81). Assuming risk equalization, the number needed to treat to prevent one infection was 15 (95% CI 9.6–38.6). In conclusion, UDI is generally well tolerated, although approximately one-third of patients experience moderate-to-severe pain or emotional discomfort. Pre-procedural bacteriuria increases infection risk, but the number needed to treat does not support antibiotic prophylaxis.
- Open Access
Real-World Short-Term Safety of Ultrasound-Guided Suprapubic Trocar Catheter Placement in Neurogenic Lower Urinary Tract Dysfunction: A Retrospective Cohort Study
Objective: To determine the incidence of severe 30-day complications (Clavien–Dindo ≥ III) after ultrasound-guided percutaneous suprapubic catheter placement in patients with neurogenic lower urinary tract dysfunction and to describe overall 30-day safety outcomes. Methods: This retrospective single-centre cohort study included adults with neurogenic lower urinary tract dysfunction who underwent first-time, non-urgent ultrasound-guided percutaneous suprapubic catheter placement between January 2019 and April 2025 and had documented follow-up for at least 30 days. Complications were graded according to the Clavien–Dindo classification; severe complications were defined as grade ≥ III. Potential risk factors were assessed using univariable logistic regression. Results: Of 300 screened patients, 287 were included. Within 30 days, 49/287 patients (17.1%; 95% CI 12.9–21.9) developed at least one complication, and 18/287 (6.3%; 95% CI 3.8–9.7) had a Clavien–Dindo grade ≥ III complication. Grade ≥ IIIb events occurred in 6/287 patients (2.1%; grade IIIb, n = 5; grade IV, n = 1). No confirmed bowel injury was observed. In an exploratory univariable analysis, diabetes mellitus showed a borderline unadjusted association with severe complications (OR 2.86; 95% CI 1.01–7.64; p = 0.049). No multivariable adjustment or multiplicity correction was performed. Conclusions: This study provides confirmatory real-world short-term safety data for selected patients with neurogenic lower urinary tract dysfunction who underwent ultrasound-guided trocar suprapubic catheter placement. No confirmed bowel injury was observed. The diabetes mellitus signal is hypothesis-generating and requires confirmation in larger studies.
Open AccessReal-World Short-Term Safety of Ultrasound-Guided Suprapubic Trocar Catheter Placement in Neurogenic Lower Urinary Tract Dysfunction: A Retrospective Cohort Study
Objective: To determine the incidence of severe 30-day complications (Clavien–Dindo ≥ III) after ultrasound-guided percutaneous suprapubic catheter placement in patients with neurogenic lower urinary tract dysfunction and to describe overall 30-day safety outcomes. Methods: This retrospective single-centre cohort study included adults with neurogenic lower urinary tract dysfunction who underwent first-time, non-urgent ultrasound-guided percutaneous suprapubic catheter placement between January 2019 and April 2025 and had documented follow-up for at least 30 days. Complications were graded according to the Clavien–Dindo classification; severe complications were defined as grade ≥ III. Potential risk factors were assessed using univariable logistic regression. Results: Of 300 screened patients, 287 were included. Within 30 days, 49/287 patients (17.1%; 95% CI 12.9–21.9) developed at least one complication, and 18/287 (6.3%; 95% CI 3.8–9.7) had a Clavien–Dindo grade ≥ III complication. Grade ≥ IIIb events occurred in 6/287 patients (2.1%; grade IIIb, n = 5; grade IV, n = 1). No confirmed bowel injury was observed. In an exploratory univariable analysis, diabetes mellitus showed a borderline unadjusted association with severe complications (OR 2.86; 95% CI 1.01–7.64; p = 0.049). No multivariable adjustment or multiplicity correction was performed. Conclusions: This study provides confirmatory real-world short-term safety data for selected patients with neurogenic lower urinary tract dysfunction who underwent ultrasound-guided trocar suprapubic catheter placement. No confirmed bowel injury was observed. The diabetes mellitus signal is hypothesis-generating and requires confirmation in larger studies.
- Open Access
- 10 August 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (3)
Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study
Background: Guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment alternative to patients who are surgically inoperable, or decline radical cystectomy. Objective: The aim of this study was to evaluate oncological outcomes in patients receiving epirubicin-based HIVEC as a second-line therapeutic approach. Methods: Retrospective inclusion of patients from our prospectively maintained, multicenter HIVEC database, who underwent HIVEC due to recurrent or persistent high-grade NMIBC following adequate BCG therapy (BCG failure) between November 2016 and December 2024. Survival was evaluated using Kaplan–Meier analysis and log-rank testing. Associations between clinicopathological factors and oncological outcomes were assessed using Cox regression analysis. Results: Sixty-five patients were included. Median follow-up was 38 months (IQR 21–55). Twenty-four patients (36.9%) experienced intravesical recurrence with a median intravesical recurrence-free survival (RFS) of 24 months (IQR 9-45) and 1-/2-year intravesical RFS rates of 77.9% and 64.1%, respectively. Extravesical recurrence was observed in 21 patients (32.3%) with a median extravesical RFS of 22 months (IQR 7-43) and 1-/2-year extravesical RFS rates of 81.3% and 70.9%, respectively. Higher number of recurrences prior to HIVEC were significantly associated with extravesical recurrence in univariate (HR 2.23; 95% CI 1.23-3.87; p=0.019) and multivariate analysis (HR 1.31; 95% CI 1.03-1.67; p=0.027). Conclusions: Although limited by the relatively small sample size, Epirubicin-based HIVEC demonstrated promising oncological outcomes indicating its potential value as bladder-preserving treatment option after BCG failure. Prospective controlled studies are warranted to further assess the role of epirubicin-based HIVEC in this setting.
- 10 August 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (3)
Open AccessIntra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study
Background: Guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment alternative to patients who are surgically inoperable, or decline radical cystectomy. Objective: The aim of this study was to evaluate oncological outcomes in patients receiving epirubicin-based HIVEC as a second-line therapeutic approach. Methods: Retrospective inclusion of patients from our prospectively maintained, multicenter HIVEC database, who underwent HIVEC due to recurrent or persistent high-grade NMIBC following adequate BCG therapy (BCG failure) between November 2016 and December 2024. Survival was evaluated using Kaplan–Meier analysis and log-rank testing. Associations between clinicopathological factors and oncological outcomes were assessed using Cox regression analysis. Results: Sixty-five patients were included. Median follow-up was 38 months (IQR 21–55). Twenty-four patients (36.9%) experienced intravesical recurrence with a median intravesical recurrence-free survival (RFS) of 24 months (IQR 9-45) and 1-/2-year intravesical RFS rates of 77.9% and 64.1%, respectively. Extravesical recurrence was observed in 21 patients (32.3%) with a median extravesical RFS of 22 months (IQR 7-43) and 1-/2-year extravesical RFS rates of 81.3% and 70.9%, respectively. Higher number of recurrences prior to HIVEC were significantly associated with extravesical recurrence in univariate (HR 2.23; 95% CI 1.23-3.87; p=0.019) and multivariate analysis (HR 1.31; 95% CI 1.03-1.67; p=0.027). Conclusions: Although limited by the relatively small sample size, Epirubicin-based HIVEC demonstrated promising oncological outcomes indicating its potential value as bladder-preserving treatment option after BCG failure. Prospective controlled studies are warranted to further assess the role of epirubicin-based HIVEC in this setting.
- Open Access
Changing Face of Radical Prostatectomy: A Nationwide Registry Study of Case-Mix, Surgical Evolution, and Outcomes
Background/Objectives: We aimed to evaluate temporal changes in patient selection, surgical practice, and postoperative outcomes of radical prostatectomy in Switzerland (2020–2025) using a national registry. Methods: Data from 7687 patients undergoing radical prostatectomy were extracted from a prospective national registry (January 2020–March 2025). Preoperative, operative, and postoperative variables were compared descriptively using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Temporal trends were assessed using locally estimated scatterplot smoothing. Multivariable logistic regression analyses were performed for positive surgical margins and PSA persistence. Results: Baseline patient characteristics remained stable over time. The use of MRI-targeted biopsy increased from 46% to 84% (p < 0.001). The proportion of low-risk diseases being treated decreased from 7.1% to 4.0% (p = 0.040). Minimally invasive surgery increased from 81% to 95% (p < 0.001); pelvic lymph node dissection declined from 83% to 63% (p < 0.001). Operative time (205 vs. 185 min, p = 0.002) and blood loss (300 vs. 200 mL, p < 0.001) decreased over time. Lymph node invasion decreased from 11% to 6.0% (p = 0.001), positive surgical margins from 27% to 22% (p = 0.044), and prostate-specific antigen persistence from 18.5% to 11.3% (p = 0.001). Severe postoperative complications decreased from 2.5% to 0.8% (p = 0.014). After multivariable adjustment, surgery performed in 2024 remained independently associated with lower rates of positive surgical margins (OR 0.73, 95% CI 0.57–0.93) and PSA persistence (OR 0.26, 95% CI 0.19–0.37) compared with 2020. Conclusions: Using the Swiss national registry, we demonstrate that radical prostatectomy has evolved toward more risk-adapted patient selection, near-universal minimally invasive surgery, and more selective pelvic lymph node dissection. Despite a shift away from low-risk disease, perioperative and early oncological outcomes improved, likely reflecting a combination of evolving diagnostic pathways, increasing surgical experience, and broader changes in perioperative management.
Open AccessChanging Face of Radical Prostatectomy: A Nationwide Registry Study of Case-Mix, Surgical Evolution, and Outcomes
Background/Objectives: We aimed to evaluate temporal changes in patient selection, surgical practice, and postoperative outcomes of radical prostatectomy in Switzerland (2020–2025) using a national registry. Methods: Data from 7687 patients undergoing radical prostatectomy were extracted from a prospective national registry (January 2020–March 2025). Preoperative, operative, and postoperative variables were compared descriptively using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Temporal trends were assessed using locally estimated scatterplot smoothing. Multivariable logistic regression analyses were performed for positive surgical margins and PSA persistence. Results: Baseline patient characteristics remained stable over time. The use of MRI-targeted biopsy increased from 46% to 84% (p < 0.001). The proportion of low-risk diseases being treated decreased from 7.1% to 4.0% (p = 0.040). Minimally invasive surgery increased from 81% to 95% (p < 0.001); pelvic lymph node dissection declined from 83% to 63% (p < 0.001). Operative time (205 vs. 185 min, p = 0.002) and blood loss (300 vs. 200 mL, p < 0.001) decreased over time. Lymph node invasion decreased from 11% to 6.0% (p = 0.001), positive surgical margins from 27% to 22% (p = 0.044), and prostate-specific antigen persistence from 18.5% to 11.3% (p = 0.001). Severe postoperative complications decreased from 2.5% to 0.8% (p = 0.014). After multivariable adjustment, surgery performed in 2024 remained independently associated with lower rates of positive surgical margins (OR 0.73, 95% CI 0.57–0.93) and PSA persistence (OR 0.26, 95% CI 0.19–0.37) compared with 2020. Conclusions: Using the Swiss national registry, we demonstrate that radical prostatectomy has evolved toward more risk-adapted patient selection, near-universal minimally invasive surgery, and more selective pelvic lymph node dissection. Despite a shift away from low-risk disease, perioperative and early oncological outcomes improved, likely reflecting a combination of evolving diagnostic pathways, increasing surgical experience, and broader changes in perioperative management.
- Open Access
- 8 December 2025
- Published by Springer Nature in Die Urologie
- Vol. 65 (1) , 64-68
Vergleich von Beckenbodentrainingsmethoden zur Therapie weiblicher Harninkontinenz
- 8 December 2025
- Published by Springer Nature in Die Urologie
- Vol. 65 (1) , 64-68
Open AccessVergleich von Beckenbodentrainingsmethoden zur Therapie weiblicher Harninkontinenz
- Open Access
- 27 January 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (3) , 523-537
Remote neurodegeneration in the lumbosacral cord one month after spinal cord injury: a cross‐sectional MRI study
Objective: To characterize structural integrity of the lumbosacral enlargement and conus medullaris within one month after spinal cord injury (SCI).Methods: Lumbosacral cord MRI data were acquired in patients with sudden onset (<7 days) SCI at the cervical or thoracic level approximately one month after injury and in healthy controls. Tissue integrity and loss were evaluated through diffusion tensor (DTI) and T2*‐weighted imaging (cross‐sectional area [CSA] measurements). Associations with the degree of neurological impairment were assessed using linear mixed‐effects models.Results: Twenty‐one patients with SCI showed lower white matter (WM) fractional anisotropy (FA) (≤−13.3%) and higher WM radial diffusivity (≤14.6%) compared to 27 healthy controls. Differences were most pronounced in the lateral columns of WM. CSA measurements revealed no group differences. For the lateral columns, lower FA values were associated with lower motor scores and lower amplitudes of motor evoked potentials. For the dorsal columns, lower FA values were associated with lower amplitudes of somatosensory evoked potentials from the lower extremities.Interpretation: One month after SCI, first signs of WM degeneration were apparent, without indication of tissue loss. The more pronounced differences observed in the lateral column could be attributed to anterograde degeneration of the motor tracts. The variability among DTI measurements remote from the lesion site can be partially explained by the degree of the SCI‐induced neurological impairment. Together with previous studies, our findings indicate that impaired tissue integrity precedes tissue loss. The presented techniques have potential applications in monitoring the progression of various neurological diseases.
- 27 January 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (3) , 523-537
Open AccessRemote neurodegeneration in the lumbosacral cord one month after spinal cord injury: a cross‐sectional MRI study
Objective: To characterize structural integrity of the lumbosacral enlargement and conus medullaris within one month after spinal cord injury (SCI).Methods: Lumbosacral cord MRI data were acquired in patients with sudden onset (<7 days) SCI at the cervical or thoracic level approximately one month after injury and in healthy controls. Tissue integrity and loss were evaluated through diffusion tensor (DTI) and T2*‐weighted imaging (cross‐sectional area [CSA] measurements). Associations with the degree of neurological impairment were assessed using linear mixed‐effects models.Results: Twenty‐one patients with SCI showed lower white matter (WM) fractional anisotropy (FA) (≤−13.3%) and higher WM radial diffusivity (≤14.6%) compared to 27 healthy controls. Differences were most pronounced in the lateral columns of WM. CSA measurements revealed no group differences. For the lateral columns, lower FA values were associated with lower motor scores and lower amplitudes of motor evoked potentials. For the dorsal columns, lower FA values were associated with lower amplitudes of somatosensory evoked potentials from the lower extremities.Interpretation: One month after SCI, first signs of WM degeneration were apparent, without indication of tissue loss. The more pronounced differences observed in the lateral column could be attributed to anterograde degeneration of the motor tracts. The variability among DTI measurements remote from the lesion site can be partially explained by the degree of the SCI‐induced neurological impairment. Together with previous studies, our findings indicate that impaired tissue integrity precedes tissue loss. The presented techniques have potential applications in monitoring the progression of various neurological diseases.
- 1 September 2018
- Published by Wiley in Clinical Anatomy
- Vol. 31 (6) , 788-796
The anatomy of the male inferior hypogastric plexus: What should we know for nerve sparing surgery
The aim of this study was to investigate the nerve supply to the structures in the male lesser pelvis and review its clinical relevance, especially during nerve sparing surgery. Three formalin‐embalmed and 16 Thiel‐embalmed male hemipelves were used. They were microdissected after repeated treatments with nitric acid diluted 1:10 with milliQ‐water. The inferior hypogastric plexus (IHP) is a fan‐like structure lateral from the rectum on the fascia of the levator ani. Nerves emerging from the proximal, solid part of the plexus follow the internal iliacal vessels and reach the prostate from dorsolateral. The innervation of the urethra and the corpora cavernosa derives from two origins: one follows the ejaculatory duct and the seminal vesicle, reaching the proximal urethra and the prostate from dorsal; the other follows the inferior vesical artery to reach the prostate from lateral, and then forms the neurovascular bundle on both sides of the prostatic fascia, spreading to the pelvic floor muscles and the corpora cavernosa along with the distal urethra. A connection between the two parts was demonstrated in approximately one third of the samples investigated. The nerve supply to the urinary bladder, the urethra, and the corpora cavernosa emerges mainly from the IHP. The innervation of the proximal urethra and its autonomic muscular structures has a dorsal (ejaculatory duct) and lateral (inferior vesical artery) origin. To maintain good erectile and continence function it is important to save both the dorsal and lateral neurovascular roots. Clin. Anat. 31:788–796, 2018.
- 1 September 2018
- Published by Wiley in Clinical Anatomy
- Vol. 31 (6) , 788-796
The anatomy of the male inferior hypogastric plexus: What should we know for nerve sparing surgery
The aim of this study was to investigate the nerve supply to the structures in the male lesser pelvis and review its clinical relevance, especially during nerve sparing surgery. Three formalin‐embalmed and 16 Thiel‐embalmed male hemipelves were used. They were microdissected after repeated treatments with nitric acid diluted 1:10 with milliQ‐water. The inferior hypogastric plexus (IHP) is a fan‐like structure lateral from the rectum on the fascia of the levator ani. Nerves emerging from the proximal, solid part of the plexus follow the internal iliacal vessels and reach the prostate from dorsolateral. The innervation of the urethra and the corpora cavernosa derives from two origins: one follows the ejaculatory duct and the seminal vesicle, reaching the proximal urethra and the prostate from dorsal; the other follows the inferior vesical artery to reach the prostate from lateral, and then forms the neurovascular bundle on both sides of the prostatic fascia, spreading to the pelvic floor muscles and the corpora cavernosa along with the distal urethra. A connection between the two parts was demonstrated in approximately one third of the samples investigated. The nerve supply to the urinary bladder, the urethra, and the corpora cavernosa emerges mainly from the IHP. The innervation of the proximal urethra and its autonomic muscular structures has a dorsal (ejaculatory duct) and lateral (inferior vesical artery) origin. To maintain good erectile and continence function it is important to save both the dorsal and lateral neurovascular roots. Clin. Anat. 31:788–796, 2018.